Diamond Hill Capital's AUPH Position Overview
Diamond Hill Capital (via Diamond Hill Capital Management INC) currently holds 92,212 shares of Aurinia Pharmaceuticals Inc. (AUPH) worth $1.47 M, representing 0.01% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Diamond Hill Capital has maintained a strategic position in AUPH, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 46,104 shares. Largest reduction occurred in Q4 2025, reducing 23,991 shares.
Analysis based on 13F filings available since 2013 Q2
Diamond Hill Capital's Aurinia Pharmaceuticals (AUPH) Holding Value Over Time
Track share changes against reported price movement
Quarterly Aurinia Pharmaceuticals (AUPH) Trades by Diamond Hill Capital
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -23,991 | Reduce 20.65% | 92,212 | $15.95 |
| Q2 2025 | +46,104 | Add 65.77% | 116,203 | $8.47 |
| Q1 2024 | +15,020 | Add 27.27% | 70,099 | $5.01 |
| Q4 2023 | +26,505 | Add 92.76% | 55,079 | $8.99 |
| Q1 2022 | +9,390 | Add 48.95% | 28,574 | $12.39 |
| Q4 2021 | +715 | Add 3.87% | 19,184 | $22.88 |
| Q2 2021 | +18,469 | New Buy | 18,469 | $12.94 |
Diamond Hill Capital's Aurinia Pharmaceuticals Investment FAQs
Diamond Hill Capital first purchased Aurinia Pharmaceuticals Inc. (AUPH) in Q2 2021, acquiring 18,469 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Diamond Hill Capital has held Aurinia Pharmaceuticals Inc. (AUPH) for 19 quarters since Q2 2021.
Diamond Hill Capital's largest addition to Aurinia Pharmaceuticals Inc. (AUPH) was in Q2 2025, adding 116,203 shares worth $984,239.
According to the latest 13F filing for Q4 2025, Diamond Hill Capital's firm, Diamond Hill Capital Management INC, owns 92,212 shares of Aurinia Pharmaceuticals Inc. (AUPH), valued at approximately $1.47 M.
As of the Q4 2025 filing, Aurinia Pharmaceuticals Inc. (AUPH) represents approximately 0.01% of Diamond Hill Capital's publicly disclosed stock portfolio, making it one of their key holdings.
Diamond Hill Capital's peak holding in Aurinia Pharmaceuticals Inc. (AUPH) was 116,203 shares, as reported at the end of Q2 2025.